Head and neck cancer:
Indications for: HYDREA
Locally advanced squamous cell carcinomas of the head and neck (excluding the lip), in combination with concurrent chemoradiation.
Adult Dosage:
Base dose on ideal or actual weight, whichever is less. Individualize. Initially 15mg/kg/day. Renal impairment (CrCl <60mL/min or ESRD): initially 7.5mg/kg/day; give dose following dialysis (monitor). Dose modifications: see full labeling.
Children Dosage:
Not established.
HYDREA Warnings/Precautions:
Risk of severe myelosuppression. Markedly depressed bone marrow function: do not initiate. Monitor CBCs prior to and during therapy; interrupt, reduce dose, or discontinue as needed. Discontinue if confirmed diagnosis of hemolytic anemia. Monitor for secondary malignancies (eg, leukemia, skin cancer). Avoid sun exposure. Previous irradiation therapy; monitor for skin erythema. Macrocytosis may mask folic acid deficiency; prophylactic folic acid is recommended. Pulmonary toxicity (monitor). Myeloproliferative disorders; discontinue if cutaneous vasculitic ulcerations occur. Renal or hepatic impairment. Elderly. Embryo-fetal toxicity. Advise to use effective contraception during and for ≥6 months (females of reproductive potential) or ≥1 year (males) after therapy. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended.
HYDREA Classification:
Antimetabolite.
HYDREA Interactions:
Avoid concomitant didanosine, with or without stavudine, or other antiretrovirals (may cause pancreatitis [monitor], fatal hepatotoxicity, peripheral neuropathy). Avoid live vaccines. Increased risk of vasculitic toxicities with interferon therapy. May cause falsely elevated results in urea, uric acid, and lactic acid assays.
Adverse Reactions:
Leukopenia, thrombocytopenia, anemia, GI upset, anorexia; secondary malignancies, macrocytosis, interstitial lung disease.
Note:
Wear disposable gloves when handling caps or bottle.
Drug Elimination:
Renal (40%).
Generic Drug Availability:
YES
How Supplied:
Caps—100
Leukemias, lymphomas, and other hematologic cancers:
Indications for: HYDREA
Resistant chronic myeloid leukemia.
Adult Dosage:
Base dose on ideal or actual weight, whichever is less. Individualize. Initially 15mg/kg/day. Renal impairment (CrCl <60mL/min or ESRD): initially 7.5mg/kg/day; give dose following dialysis (monitor). Dose modifications: see full labeling.
Children Dosage:
Not established.
HYDREA Warnings/Precautions:
Risk of severe myelosuppression. Markedly depressed bone marrow function: do not initiate. Monitor CBCs prior to and during therapy; interrupt, reduce dose, or discontinue as needed. Discontinue if confirmed diagnosis of hemolytic anemia. Monitor for secondary malignancies (eg, leukemia, skin cancer). Avoid sun exposure. Previous irradiation therapy; monitor for skin erythema. Macrocytosis may mask folic acid deficiency; prophylactic folic acid is recommended. Pulmonary toxicity (monitor). Myeloproliferative disorders; discontinue if cutaneous vasculitic ulcerations occur. Renal or hepatic impairment. Elderly. Embryo-fetal toxicity. Advise to use effective contraception during and for ≥6 months (females of reproductive potential) or ≥1 year (males) after therapy. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended.
HYDREA Classification:
Antimetabolite.
HYDREA Interactions:
Avoid concomitant didanosine, with or without stavudine, or other antiretrovirals (may cause pancreatitis [monitor], fatal hepatotoxicity, peripheral neuropathy). Avoid live vaccines. Increased risk of vasculitic toxicities with interferon therapy. May cause falsely elevated results in urea, uric acid, and lactic acid assays.
Adverse Reactions:
Leukopenia, thrombocytopenia, anemia, GI upset, anorexia; secondary malignancies, macrocytosis, interstitial lung disease.
Note:
Wear disposable gloves when handling caps or bottle.
Drug Elimination:
Renal (40%).
Generic Drug Availability:
YES
How Supplied:
Caps—100
